In a noteworthy development within the medical-device and health-technology assessment (HTA) landscape, Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) announced that its microwave ablation (MWA) system has achieved Medicare reimbursement at a prominent New York endocrinology practice. This reimbursement milestone represents a key access and commercial inflection point for the minimally invasive treatment of thyroid nodules, with meaningful implications for device manufacturers, payers and clinical sites.
Market access breakthrough
Baird Medical said its MWA procedures performed at the Elk Medical practice in Brooklyn, were accepted by Medicare for reimbursement following nine procedures undertaken in recent months. While the number of cases is small, the significance lies in payer validation of the therapy and the establishment of reimbursement precedent in a U.S. real-world setting.
The reimbursement of MWA at this site sends signals. First, non-surgical alternatives for thyroid nodules are gaining recognition as cost-effective and patient-centred modalities. Second, device manufacturers must align launch strategy with payer demands for real-world adoption, coding clarity and sufficient economic modelling (e.g., reduced surgical complications, faster recovery, fewer hospital stays).
For Baird Medical, the market-access playbook now shifts toward scaling: securing additional site adoption, collecting broader outcome data, aligning with insurer networks and negotiating with commercial payors beyond Medicare. The company is likely to highlight improved patient turnaround, lower complication rates and potentially lower total cost of care compared to conventional surgery.